Alexandra Balcom Nuvalent, Inc. (NUVL) insider trading activity

Alexandra Balcom is Chief Financial Officer of Nuvalent, Inc.. Currently has a direct ownership of 61,734 shares of NUVL, which is worth approximately $6.05 Million. The most recent transaction as insider was on Oct 15, 2025, when has been sold 1,683 shares (Class A Common Stock) at a price of $85.57 per share, resulting in proceeds of $144,014. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 61.7K

0% 3M change

85.39% 12M change

Total Value Held $6.05 Million

Alexandra Balcom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 15 2025	SELL Open market or private sale	$144,014 $85.57 p/Share	1,683 Reduced 2.65%	61,734 Class A Common Stock
Oct 15 2025	BUY Exercise of conversion of derivative security	$31,859 $18.93 p/Share	1,683 Added 2.59%	63,417 Class A Common Stock
Oct 14 2025	SELL Open market or private sale	$1,744,800 $87.24 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 14 2025	BUY Exercise of conversion of derivative security	$378,600 $18.93 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Oct 13 2025	SELL Open market or private sale	$1,772,400 $88.62 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 13 2025	BUY Exercise of conversion of derivative security	$258,200 $12.91 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Oct 01 2025	SELL Open market or private sale	$1,718,000 $85.9 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 01 2025	BUY Exercise of conversion of derivative security	$258,200 $12.91 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Sep 30 2025	SELL Open market or private sale	$1,701,200 $85.06 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Sep 30 2025	BUY Exercise of conversion of derivative security	$137,800 $6.89 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Sep 29 2025	SELL Open market or private sale	$645,055 $85.01 p/Share	7,588 Reduced 10.95%	61,734 Class A Common Stock
Sep 29 2025	BUY Exercise of conversion of derivative security	$52,281 $6.89 p/Share	7,588 Added 9.87%	69,322 Class A Common Stock
Jul 16 2025	SELL Open market or private sale	$1,250,970 $85.1 p/Share	14,700 Reduced 19.23%	61,734 Class A Common Stock
Jul 16 2025	BUY Exercise of conversion of derivative security	$278,271 $18.93 p/Share	14,700 Added 16.13%	76,434 Class A Common Stock
Jul 15 2025	SELL Open market or private sale	$446,419 $84.23 p/Share	5,300 Reduced 7.91%	61,734 Class A Common Stock
Jul 15 2025	BUY Exercise of conversion of derivative security	$100,329 $18.93 p/Share	5,300 Added 7.33%	67,034 Class A Common Stock
Jun 27 2025	SELL Open market or private sale	$1,600,400 $80.02 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Jun 27 2025	BUY Exercise of conversion of derivative security	$378,600 $18.93 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Jan 06 2025	SELL Open market or private sale	$318,790 $79.38 p/Share	4,016 Reduced 6.11%	61,734 Class A Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	18,750 Added 22.19%	65,750 Class A Common Stock
Dec 17 2024	BUY Exercise of conversion of derivative security	$54,663 $3.99 p/Share	13,700 Added 22.57%	47,000 Class A Common Stock
Nov 29 2024	SELL Open market or private sale	$959,700 $95.97 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Nov 29 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Oct 31 2024	SELL Open market or private sale	$896,700 $89.67 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Oct 31 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

Director